Almac has launched a tumor profiling service running Illumina’s next-generation sequencing (NGS) TruSight Tumor panel as part of their biomarker discovery, development and delivery solutions.

Almac, a personalized medicine company with CAP accredited and CLIA certified laboratories, offers TruSight Tumor to complement its current range of RNA, DNA and protein based technologies for biomarker analysis. 

Almac is currently running bespoke diagnostic assays for pharma customers for early phase clinical trial enrichment. The TruSight Tumor panel enables additional profiling of these patient samples to provide Almac’s pharma partners with further information on emerging biomarkers that may also impact drug response.

The TruSight Tumor panel was developed by Illumina for its MiSeq system, allowing targeted DNA sequencing and reporting on the mutation status of 26 genes which are most commonly mutated in solid tumors including lung, colon, ovarian, melanoma and gastric cancers. 

The panel is specifically designed for use with FFPE samples, and enables the highest levels of sensitivity for mutation detection with limited DNA input requirements.